In this respect, the gastrin-releasing peptide receptor (GRPR) has attracted considerable attention as a promising biomolecular target in nuclear oncology, due to its high-density expression in frequently occurring human cancers (prostate and breast cancer) [5,6,7,8,9,10,11,12]. This evidence concerns the gene GRPR and breast cancer.